APA (7th ed.) Citation

Scagliotti, G. V., Moro-Sibilot, D., Kollmeier, J., Favaretto, A., Cho, E. K., Grosch, H., . . . Chang, G. (2020). A randomized-controlled phase 2 study of the MET antibody emibetuzumab in combination with erlotinib as first-line treatment for EGFR mutation-positive NSCLC patients. Journal of thoracic oncology, 15(1), . https://doi.org/10.1016/j.jtho.2019.10.003

Chicago Style (17th ed.) Citation

Scagliotti, Giorgio V., et al. "A Randomized-controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR Mutation-positive NSCLC Patients." Journal of Thoracic Oncology 15, no. 1 (2020). https://doi.org/10.1016/j.jtho.2019.10.003.

MLA (9th ed.) Citation

Scagliotti, Giorgio V., et al. "A Randomized-controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR Mutation-positive NSCLC Patients." Journal of Thoracic Oncology, vol. 15, no. 1, 2020, https://doi.org/10.1016/j.jtho.2019.10.003.